Tag: KDC-MN-1633

  • Resmetirom

    Liver-directed, beta-selective thyroid hormone receptor agonist (thyromimetic)

    A first-in-class, orally administered, hepatocyte-targeted partial agonist of thyroid hormone receptor beta developed by Madrigal Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis, and the first pharmacotherapy approved by the United States Food and Drug Administration for this indication.

    Abstract

    Resmetirom (MGL-3196, VIA-3196; marketed as Rezdiffra) is a first-in-class, orally administered, small-molecule, liver-directed partial agonist of the thyroid hormone receptor beta (THR-beta) that received accelerated approval from the United States Food and Drug Administration on March 14, 2024, for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis or NASH) with moderate to advanced liver fibrosis (stages F2 to F3), in conjunction with diet and exercise. Resmetirom is distinguished from earlier thyromimetic compounds by approximately 28-fold functional selectivity for THR-beta over THR-alpha, hepatocyte-directed uptake mediated by organic anion transporting polypeptide 1B1 (OATP1B1), and a liver-to-plasma concentration ratio of approximately 8:1, properties that collectively minimize the extrahepatic thyrotoxic effects (tachycardia, bone loss, skeletal muscle wasting) that terminated development of prior thyroid hormone receptor agonists including eprotirome and sobetirome. The molecular mechanism involves activation of THR-beta in hepatocytes, promoting fatty acid beta-oxidation, mitochondrial biogenesis, mitophagy, and autophagy while inhibiting de novo lipogenesis; these effects reduce intrahepatic triglyceride accumulation and attenuate the inflammatory and fibrotic cascades characteristic of progressive steatohepatitis. Secondary endpoints demonstrated reductions in low-density lipoprotein cholesterol (16.3 percent), apolipoprotein B (16.5 percent), and triglycerides (23.4 percent), consistent with the hepatic metabolic mechanism. Pharmacokinetics are characterized by oral absorption with a median time to peak concentration of approximately 4 hours, greater than 99 percent plasma protein binding, a median terminal half-life of 4.5 hours, metabolism predominantly through cytochrome P450 2C8 (CYP2C8), and elimination principally via feces (67 percent) with a minor renal component (24 percent). The principal adverse events are diarrhea and nausea, which are generally mild to moderate and self-limiting. Clinically significant drug interactions include inhibition of organic anion transporting polypeptide transporters (elevating statin exposures) and CYP2C8-mediated metabolic interactions. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.